Intangible Assets

Novo Nordisk’s GLP-1 and diabetes franchises benefit from patent protection and regulatory exclusivity, which supports pricing power versus generic insulin and smaller peptide peers.

Its branded prescription medicines are embedded in physician prescribing and payer formularies, which makes substitution slower than for over-the-counter or commoditized therapies.

The company’s long clinical history in diabetes and obesity gives it credibility with prescribers and payers, which helps defend share versus newer entrants such as Eli Lilly’s incretin portfolio and smaller biotech competitors.

Intellectual property is strong but time-bound, so the moat is durable over the medium term rather than structurally permanent, especially as patent cliffs and biosimilar pathways approach in parts of the portfolio.

Switching Costs

Patients on chronic diabetes and obesity therapies face practical switching friction because dose titration, tolerability, and adherence are managed over time, which supports retention versus episodic-treatment peers.

Physicians and payers often prefer continuity on a therapy that is already working, which reduces switching unless a competitor offers clearly better efficacy, access, or supply.

Novo Nordisk’s scale in chronic care creates operational familiarity for providers and pharmacies, which lowers the likelihood of frequent switching relative to smaller specialty-drug peers.

Switching costs are meaningful but not absolute because payers can force formulary changes and Eli Lilly can win switches with superior clinical or commercial terms.

Network Effects

Novo Nordisk does not operate a true network platform, so customer value does not compound through direct user-to-user effects as it would for software or marketplaces.

Prescriber and payer adoption can create some indirect momentum, but that is not a self-reinforcing network effect and is weaker than the ecosystem effects seen in platform businesses.

Compared with peers, the company’s advantage comes from clinical efficacy and access rather than from a network that becomes more valuable as more users join.

Any data or real-world evidence benefits are important for commercialization, but they do not create durable network lock-in on their own.

Cost Advantage

Novo Nordisk’s very high ROIC and ROCE indicate that its capital base is being converted into earnings efficiently, which is consistent with a strong cost position versus many pharma peers.

Large-scale manufacturing and global distribution in chronic injectable and oral therapies support lower unit costs than smaller competitors, which helps preserve margins when pricing pressure rises.

Its focused portfolio in diabetes and obesity allows operating leverage across a concentrated therapeutic area, which is more efficient than diversified peers with fragmented R&D and commercial spend.

Eli Lilly is the closest cost-and-scale rival in incretins, so Novo’s advantage is strong but not exclusive, and competitive investment can narrow the gap over time.

Efficient Scale

Novo Nordisk operates in large chronic disease markets where scale in manufacturing, regulatory execution, and global commercialization lowers average cost and strengthens competitive positioning.

The company’s leadership in diabetes and obesity creates a scale advantage because fixed R&D, clinical, and supply-chain investments are spread across a very large revenue base.

In a market with only a few credible global incretin competitors, scale matters because capacity, supply reliability, and payer access can determine share retention versus smaller peers.

This is close to exceptional but not structural dominance because Eli Lilly remains a powerful peer and the market can still support more than one large winner.

Overall Score

Novo Nordisk has a strong and durable moat driven mainly by patents and regulatory protection, meaningful switching costs in chronic care, and efficient scale in a concentrated therapeutic area, but it falls short of exceptional structural dominance because network effects are weak and Eli Lilly remains a credible peer with comparable strategic strength.